Meet SenzaGen group companies VitroScreen and ToxHub at the 65th AFI Symposium, June 10-12, at the Palacongressi in Rimini.

Meet SenzaGen Group at booth No. 5

At the event, VitroScreen and ToxHub will showcase how our combined scientific capabilities support pharma and medical device development through non-animal safety and efficacy testing approaches, and regulatory toxicology and pharmacology consultancy.

Posters: Film-forming effect, biorevitalizing activity of hyaluronic acid–based devices

VitroScreen will present new preclinical data using advanced human-relevant models for non-animal efficacy testing of substance-based medical devices, including the spheroid-based platform VitroScreenORA:

🎫 Assessment of the film-forming effect of substance-based medical devices on reconstructed human epithelia in vitro

🎫 Preclinical evaluation of the biorevitalizing activity of hyaluronic acid–based medical devices using an innovative aged human dermal spheroid platform

ToxHub contributes with expertise in regulatory toxicology and risk assessment, with a special focus on impurity qualification:

🎫 The qualification for non-mutagenic impurities for high potent APIs